Article

Therapeutic potential of T cell receptor targeting the HLA-A*11:01-restricted KRASG12V neoantigen without cross-recognition of the self-antigen RAB7B in solid tumors

2025-02-20

Abstract excerpt

<title>Abstract</title> <p><bold>Background</bold> Public neoantigens, including KRAS, TP53, and PIK3CA mutations, which are shared across various tumor types, have demonstrated significant immunogenicity and offer great promise for cancer immunotherapy. Clinical trials targeting these public neoantigens have yielded encouraging results, including tumor regression and prolonged relapse-free survival. This study e...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 3f8b685f-41b3-56ad-afda-bdd930f006db
DOI: 10.21203/rs.3.rs-6054034/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Therapeutic potential of T cell receptor targeting the HLA-A*11:01-restricted KRASG12V neoantigen without cross-recognition of the self-antigen RAB7B in solid tumorsDOI 10.21203/rs.3.rs-6054034/v1Read

Identification of novel KRASG12D neoantigen specific TCRs and a strategy to eliminate off-target recognitionSemantic proximity Read

Natural TCRs targeting KRASG12V display fine specificity and sensitivity to human solid tumorsSemantic proximity Read

KRAS G12V neoantigen specific T cell receptor for adoptive T cell therapy against tumorsSemantic proximity Read

Targeting Driver Oncogenes and Other Public Neoantigens Using T Cell Receptor–Based Cellular TherapySemantic proximity Read

Dual-degenerate TCRs target multiple KRAS hotspot and HLA-A3 family combinationsSemantic proximity Read

Identification and affinity enhancement of T-cell receptor targeting a KRASG12V cancer neoantigen.Semantic proximity Read

Identification and structural characterization of a mutant KRAS-G12V specific TCR restricted by HLA-A3.Semantic proximity Read

Generation of T cell responses against broad KRAS hotspot neoantigens for cell therapy or TCR discoverySemantic proximity Read

Targeting KRASG12V mutations with HLA class II-restricted TCR for the immunotherapy in solid tumors.Semantic proximity Read

Functional avidity enhancement of a T-cell receptor targeting the KRASG12D cancer neoantigen.Semantic proximity Read

Identification and Structural Characterization of a mutant KRAS-G12V specific TCR restricted by HLA-A3Semantic proximity Read

KRASG12V/HLA-A*02:01-targeted chimeric antigen receptor T cells exhibit potent preclinical activity against solid tumors.Semantic proximity Read